TY - JOUR
T1 - Philadelphia-positive acute lymphoblastic leukemia
T2 - Current treatment options
AU - Liu-Dumlao, Theresa
AU - Kantarjian, Hagop
AU - Thomas, Deborah A.
AU - O'Brien, Susan
AU - Ravandi, Farhad
PY - 2012/10
Y1 - 2012/10
N2 - The Philadelphia chromosome (Ph), t(9;22), is seen in about 20 % to 30 % of adults diagnosed with acute lymphoblastic leukemia (ALL). It has been associated with poorer prognosis compared with Ph-negative ALL. Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL oncogenic protein from this translocation have been incorporated into treatment regimens used to treat patients with Ph-positive ALL. Imatinib has been the most widely used TKI with several published trials showing it produced better outcomes when combined with chemotherapy. Dasatinib, a more potent inhibitor than imatinib, has also been evaluated with promising results. However, relapses still occur at a high rate, and allogeneic stem cell transplant is considered, so far, a better curative option in first remission. Additional strategies have also included incorporation of TKIs in the posttransplant setting and the use of newer third generation TKIs. This review provides an update on emerging therapies for adults with Ph-positive ALL.
AB - The Philadelphia chromosome (Ph), t(9;22), is seen in about 20 % to 30 % of adults diagnosed with acute lymphoblastic leukemia (ALL). It has been associated with poorer prognosis compared with Ph-negative ALL. Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL oncogenic protein from this translocation have been incorporated into treatment regimens used to treat patients with Ph-positive ALL. Imatinib has been the most widely used TKI with several published trials showing it produced better outcomes when combined with chemotherapy. Dasatinib, a more potent inhibitor than imatinib, has also been evaluated with promising results. However, relapses still occur at a high rate, and allogeneic stem cell transplant is considered, so far, a better curative option in first remission. Additional strategies have also included incorporation of TKIs in the posttransplant setting and the use of newer third generation TKIs. This review provides an update on emerging therapies for adults with Ph-positive ALL.
KW - ALL
KW - Allogeneic stem cell transplant
KW - Philadelphia chromosome
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84870549149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870549149&partnerID=8YFLogxK
U2 - 10.1007/s11912-012-0247-7
DO - 10.1007/s11912-012-0247-7
M3 - Article
C2 - 22669492
AN - SCOPUS:84870549149
SN - 1523-3790
VL - 14
SP - 387
EP - 394
JO - Current oncology reports
JF - Current oncology reports
IS - 5
ER -